Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APYX Apyx Medical	$2.24 +17.9%	$1.48	$0.76 ▼ $2.30	$71.81M	1.21	80,894 shs	98,972 shs
BWAY Brainsway	$13.10 +6.2%	$10.03	$5.67 ▼ $13.25	$232.97M	1.32	67,447 shs	94,490 shs
CATX Perspective Therapeutics	$3.62 -5.0%	$2.79	$1.60 ▼ $16.55	$268.71M	1.09	1.09 million shs	1.13 million shs
LNSR LENSAR	$12.55 +0.4%	$13.45	$3.50 ▼ $17.31	$147.40M	0.52	85,135 shs	75,429 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APYX Apyx Medical	+17.89%	+30.99%	+27.27%	+72.31%	+65.93%
BWAY Brainsway	+6.24%	+18.77%	+23.00%	+40.86%	+110.27%
CATX Perspective Therapeutics	-4.99%	+4.93%	+50.83%	+64.55%	-61.93%
LNSR LENSAR	+0.40%	+2.20%	-7.58%	-11.18%	+185.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APYX Apyx Medical	2.4919 of 5 stars	0.0	5.0	4.2	2.5	1.7	0.6
BWAY Brainsway	1.3418 of 5 stars	1.5	3.0	0.0	2.0	0.8	1.9
CATX Perspective Therapeutics	3.5968 of 5 stars	4.6	3.0	0.0	3.0	2.5	0.0
LNSR LENSAR	1.2594 of 5 stars	2.0	3.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APYX Apyx Medical	2.67	Moderate Buy	N/A	N/A
BWAY Brainsway	3.00	Buy	$14.25	8.78% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	246.84% Upside
LNSR LENSAR	2.00	Hold	$15.00	19.52% Upside

Current Analyst Ratings Breakdown

Latest APYX, LNSR, BWAY, and CATX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/9/2025	BWAY Brainsway	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
4/7/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $10.00
3/31/2025	CATX Perspective Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/27/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $15.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APYX Apyx Medical	$48.10M	1.76	N/A	N/A	$0.38 per share	5.89
BWAY Brainsway	$41.02M	6.04	$0.26 per share	49.45	$3.31 per share	3.96
CATX Perspective Therapeutics	$1.43M	187.91	N/A	N/A	$2.67 per share	1.36
LNSR LENSAR	$53.49M	2.77	N/A	N/A	$0.42 per share	29.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APYX Apyx Medical	-$23.46M	-$0.55	N/A	N/A	N/A	-42.37%	-156.85%	-31.92%	8/6/2025 (Estimated)
BWAY Brainsway	$2.92M	$0.20	65.50	81.88	N/A	9.01%	7.35%	4.72%	8/5/2025 (Estimated)
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/11/2025 (Estimated)
LNSR LENSAR	-$31.40M	-$4.85	N/A	∞	N/A	-99.17%	-737.30%	-81.69%	8/6/2025 (Estimated)

Latest APYX, LNSR, BWAY, and CATX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BWAY Brainsway	$0.02	$0.04	+$0.02	$0.04	$11.45 million	$11.54 million
5/8/2025	Q1 2025	APYX Apyx Medical	-$0.13	-$0.10	+$0.03	-$0.10	$9.39 million	$9.43 million
5/8/2025	Q1 2025	LNSR LENSAR	-$0.1550	-$2.32	-$2.1650	-$2.32	$13.40 million	$11.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APYX Apyx Medical	N/A	N/A	N/A	N/A	N/A
BWAY Brainsway	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
LNSR LENSAR	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APYX Apyx Medical	3.21	5.45	4.64
BWAY Brainsway	N/A	5.03	4.75
CATX Perspective Therapeutics	N/A	9.60	9.60
LNSR LENSAR	N/A	1.81	1.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APYX Apyx Medical	55.33%
BWAY Brainsway	30.11%
CATX Perspective Therapeutics	54.66%
LNSR LENSAR	40.15%

Insider Ownership

Company	Insider Ownership
APYX Apyx Medical	16.80%
BWAY Brainsway	19.00%
CATX Perspective Therapeutics	3.72%
LNSR LENSAR	38.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APYX Apyx Medical	270	37.79 million	31.45 million	Optionable
BWAY Brainsway	120	18.90 million	15.31 million	Not Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
LNSR LENSAR	110	11.79 million	7.25 million	Optionable

APYX, LNSR, BWAY, and CATX Headlines

Recent News About These Companies

LENSAR (NASDAQ:LNSR) Stock Price Up 2% - Here's What Happened

June 25 at 2:20 AM | marketbeat.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of Shareholders

June 11, 2025 | morningstar.comM

$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of SVT, SSBK, LNSR, iCAD to Act

June 10, 2025 | morningstar.comM

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SWTX, ICAD, SSBK on Behalf of Shareholders

June 5, 2025 | morningstar.comM

LENSAR, Inc. Grants 3,090 Restricted Stock Units to New Employees as Inducement for Employment

June 4, 2025 | nasdaq.com

$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Is Investigating the Merger: SSBK, LNSR, iCAD and BSGM

June 3, 2025 | morningstar.comM

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

June 3, 2025 | businesswire.com

Short Interest in LENSAR, Inc. (NASDAQ:LNSR) Decreases By 27.0%

June 2, 2025 | marketbeat.com

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

LENSAR Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025 | globenewswire.com

Is LENSAR (LNSR) a Deeply Undervalued Stock?

April 10, 2025 | msn.com

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

March 26, 2025 | businesswire.com

Lensar downgraded to Hold from Buy at Lake Street

March 26, 2025 | markets.businessinsider.com

ALC Stock Rises Following the Merger Agreement With LENSAR

March 25, 2025 | zacks.com

Lake Street Downgrades LENSAR (LNSR)

March 25, 2025 | msn.com

Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders

March 24, 2025 | tmcnet.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating LENSAR, Inc. Buyout

March 24, 2025 | markets.businessinsider.com

Lake Street Reaffirms Their Buy Rating on LENSAR (LNSR)

March 24, 2025 | markets.businessinsider.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of LENSAR, Inc. - LNSR

March 24, 2025 | prnewswire.com

LNSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LENSAR, Inc. Is Fair to Shareholders

March 24, 2025 | businesswire.com

LENSAR - Top Healthcare Equipment Stock

March 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APYX, LNSR, BWAY, and CATX Company Descriptions

Apyx Medical NASDAQ:APYX

$2.24 +0.34 (+17.89%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.22 -0.03 (-1.12%)

As of 06/26/2025 04:04 PM Eastern

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Brainsway NASDAQ:BWAY

$13.10 +0.77 (+6.24%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$13.12 +0.02 (+0.11%)

As of 06/26/2025 04:04 PM Eastern

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Perspective Therapeutics NYSE:CATX

$3.62 -0.19 (-4.99%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$3.68 +0.06 (+1.63%)

As of 06/26/2025 07:55 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

LENSAR NASDAQ:LNSR

$12.55 +0.05 (+0.40%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$12.56 +0.00 (+0.04%)

As of 06/26/2025 04:04 PM Eastern

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time